Clinical commissioning policy: ranibizumab in retinopathy of prematurity

Document first published:: 30 May 2023
Page updated:: 30 May 2023
Topic:: Commissioning, Eye health, Maternity, Specialised commissioning
Publication type:: Policy or strategy

This policy is focused on preterm babies with retinopathy of prematurity and the use of ranibizumab in this population.

Document

Clinical commissioning policy: ranibizumab in retinopathy of prematurity

Clinical commissioning policy: ranibizumab in retinopathy of prematurity

PDF
188 KB
8 pages

Document

Clinical priorities advisory group summary report: ranibizumab in retinopathy of prematurity

Clinical priorities advisory group summary report: ranibizumab in retinopathy of prematurity

PDF
242 KB
20 pages

Document

Clinical panel report: ranibizumab in retinopathy of prematurity

Clinical panel report: ranibizumab in retinopathy of prematurity

PDF
80 KB
2 pages

Document

Evidence review: ranibizumab in retinopathy of prematurity

Evidence review: ranibizumab in retinopathy of prematurity

PDF
970 KB
91 pages

Document

Engagement report: ranibizumab in retinopathy of prematurity

Engagement report: ranibizumab in retinopathy of prematurity

PDF
146 KB
6 pages

Document

Equality and health inequalities impact assessment (EHIA): ranibizumab in retinopathy of prematurity

Equality and health inequalities impact assessment (EHIA): ranibizumab in retinopathy of prematurity

PDF
154 KB
15 pages